FVR Suomen rokotetutkimus Oy

Research at Seinäjoen Rokotetutkimusklinikka focuses on preventing serious bacterial infections in newborns by testing vaccines that target maternal and infant immunity. The primary effort evaluates a Group B streptococcus vaccine to protect both mother and child.

• Group B streptococcus vaccine safety in pregnancy
• Induction of anti‑CPS IgG antibodies for protection
• Maternal immunization to reduce newborn disease
• Monovalent pneumococcal conjugate safety and immunogenicity in toddlers

FVR Suomen rokotetutkimus Oy supports these studies with a dedicated team of investigators.

The clinic is investigating new strategies to reduce severe lower‑respiratory infections caused by RSV in infants and high‑risk children. A key trial compares the investigational monoclonal antibody MK‑1654 with the standard treatment palivizumab.

• RSV vaccine efficacy in infants and toddlers
• Comparison of MK‑1654 with palivizumab for safety and efficacy
• Incidence of medically attended lower respiratory infections
• Safety profile of RSV monoclonal antibodies across seasons

The research team at Seinäjoen Rokotetutkimusklinikka aims to lower hospitalizations due to severe respiratory disease.

Broader viral disease research at the site includes evaluating vaccine candidates that aim to prevent viral respiratory illnesses in early childhood. These studies address challenges related to virus diseases by measuring protection and safety outcomes.

• Assessment of vaccine‑induced protection against viral respiratory pathogens
• Safety monitoring of viral vaccine candidates in toddlers
• Immunogenicity profiling of novel viral antigens
• Evaluation of viral load reduction after vaccination

Ongoing work contributes to global efforts to control common viral infections in pediatric populations.

Studies emphasize the underlying immune system processes that drive protection, measuring antibody responses and safety outcomes across maternal and pediatric vaccine trials. Researchers track immunogenicity markers to predict vaccine effectiveness.

• Immunogenicity assessments of maternal vaccines
• Antibody level predictions for protection against early‑onset disease
• Safety monitoring of vaccine candidates in infants and pregnant women
• Evaluation of immune response biomarkers across study arms

The collaborative environment at FVR Suomen rokotetutkimus Oy enables detailed analysis of how the immune system responds to new preventive therapies.